JP2012515534A - Ｃ型肝炎ウイルス核酸を増幅する方法 - Google Patents

Ｃ型肝炎ウイルス核酸を増幅する方法 Download PDF

Info

Publication number
JP2012515534A
JP2012515534A JP2011546450A JP2011546450A JP2012515534A JP 2012515534 A JP2012515534 A JP 2012515534A JP 2011546450 A JP2011546450 A JP 2011546450A JP 2011546450 A JP2011546450 A JP 2011546450A JP 2012515534 A JP2012515534 A JP 2012515534A
Authority
JP
Japan
Prior art keywords
seq
nucleotide sequence
nucleotides
primer
nucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011546450A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012515534A5 (enExample
Inventor
アン ディー． クォン，
ジェームズ ダニエル フランツ，
ダグラス ジェイ． バーテルズ，
チャオ リン，
ベンジャミン シェームズ，
シェイラ シーパーサウド，
ジュディス エー． リプキ，
タラ エル． キーファー，
イー チョウ，
アイリーン ゼット． チャン，
ジェームズ シー． サリバン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vertex Pharmaceuticals Inc
Original Assignee
Vertex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharmaceuticals Inc filed Critical Vertex Pharmaceuticals Inc
Publication of JP2012515534A publication Critical patent/JP2012515534A/ja
Publication of JP2012515534A5 publication Critical patent/JP2012515534A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/706—Specific hybridization probes for hepatitis
    • C12Q1/707—Specific hybridization probes for hepatitis non-A, non-B Hepatitis, excluding hepatitis D
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2531/00—Reactions of nucleic acids characterised by
    • C12Q2531/10—Reactions of nucleic acids characterised by the purpose being amplify/increase the copy number of target nucleic acid
    • C12Q2531/113—PCR

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Pathology (AREA)
  • Virology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2011546450A 2009-01-21 2010-01-21 Ｃ型肝炎ウイルス核酸を増幅する方法 Pending JP2012515534A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14608309P 2009-01-21 2009-01-21
US61/146,083 2009-01-21
PCT/US2010/021589 WO2010090857A2 (en) 2009-01-21 2010-01-21 Methods for amplifying hepatitis c virus nucleic acids

Publications (2)

Publication Number Publication Date
JP2012515534A true JP2012515534A (ja) 2012-07-12
JP2012515534A5 JP2012515534A5 (enExample) 2013-03-07

Family

ID=42334055

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011546450A Pending JP2012515534A (ja) 2009-01-21 2010-01-21 Ｃ型肝炎ウイルス核酸を増幅する方法

Country Status (13)

Country Link
US (2) US8679740B2 (enExample)
EP (1) EP2389452A2 (enExample)
JP (1) JP2012515534A (enExample)
KR (1) KR20120101278A (enExample)
CN (1) CN102341506A (enExample)
AU (1) AU2010210892A1 (enExample)
CA (1) CA2749969A1 (enExample)
IL (1) IL214195A0 (enExample)
MX (1) MX2011007693A (enExample)
NZ (1) NZ594155A (enExample)
RU (1) RU2011134857A (enExample)
WO (1) WO2010090857A2 (enExample)
ZA (1) ZA201105349B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022513704A (ja) * 2018-12-03 2022-02-09 ダイアグノスティクス フォー ザ リアル ワールド， リミテッド Ｈｃｖ検出

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2934220C (en) 2007-10-02 2019-11-05 Theranos, Inc. Modular point-of-care devices and uses thereof
JP5945282B2 (ja) 2011-01-21 2016-07-05 セラノス， インコーポレイテッド 試料使用の極大化のためのシステム及び方法
US8475739B2 (en) 2011-09-25 2013-07-02 Theranos, Inc. Systems and methods for fluid handling
US9619627B2 (en) 2011-09-25 2017-04-11 Theranos, Inc. Systems and methods for collecting and transmitting assay results
US9632102B2 (en) 2011-09-25 2017-04-25 Theranos, Inc. Systems and methods for multi-purpose analysis
US20140170735A1 (en) 2011-09-25 2014-06-19 Elizabeth A. Holmes Systems and methods for multi-analysis
US9664702B2 (en) 2011-09-25 2017-05-30 Theranos, Inc. Fluid handling apparatus and configurations
US9268915B2 (en) 2011-09-25 2016-02-23 Theranos, Inc. Systems and methods for diagnosis or treatment
US8840838B2 (en) 2011-09-25 2014-09-23 Theranos, Inc. Centrifuge configurations
US10012664B2 (en) 2011-09-25 2018-07-03 Theranos Ip Company, Llc Systems and methods for fluid and component handling
US9810704B2 (en) 2013-02-18 2017-11-07 Theranos, Inc. Systems and methods for multi-analysis
US9250229B2 (en) 2011-09-25 2016-02-02 Theranos, Inc. Systems and methods for multi-analysis
MX356055B (es) * 2013-09-06 2018-05-11 Theranos Ip Co Llc Sistemas y métodos para detectar enfermedades infecciosas.
BR112016004955B1 (pt) 2013-09-06 2021-10-26 Labrador Diagnostics Llc Dispositivos, sistemas, métodos e conjuntos para receber cotonete
CN106222306A (zh) * 2016-08-30 2016-12-14 合肥金域医学检验所有限公司 一种hcv病毒ns5a蛋白编码序列突变检测试剂盒

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003088382A (ja) * 2001-09-18 2003-03-25 Toshiba Corp インターフェロンを投与されるべき個体においてインターフェロン療法の有効性を予測する方法、その方法をコンピュータにより実行させるためのプログラム、インターフェロン感受性に関連する多型部位の遺伝子型を検出するための核酸プローブ、およびその核酸プローブを具備する塩基配列検出用チップ
WO2003085084A2 (en) * 2002-04-03 2003-10-16 Smithkline Beecham Corporation Hepatitis c virus sub-genomic replicons
WO2006085407A1 (ja) * 2005-02-09 2006-08-17 Nihon University Hcv量に関連する遺伝子のスクリーニング方法
JP2008005849A (ja) * 2007-08-10 2008-01-17 Toshiba Corp 標的核酸の遺伝子型、および変異の判定方法、不溶性支持体に核酸断片を固定化する方法、所望の核酸を精製し、かつ増幅するための方法、並びに遺伝子型アッセイキット
WO2008136470A1 (ja) * 2007-04-27 2008-11-13 Advanced Life Science Institute, Inc. Ｈｃｖ遺伝子

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4415732A (en) 1981-03-27 1983-11-15 University Patents, Inc. Phosphoramidite compounds and processes
US4973679A (en) 1981-03-27 1990-11-27 University Patents, Inc. Process for oligonucleo tide synthesis using phosphormidite intermediates
DE3329892A1 (de) 1983-08-18 1985-03-07 Köster, Hubert, Prof. Dr., 2000 Hamburg Verfahren zur herstellung von oligonucleotiden
FR2596761B1 (fr) 1986-04-08 1988-05-20 Commissariat Energie Atomique Derives de nucleosides et leur utilisation pour la synthese d'oligonucleotides
US5322770A (en) 1989-12-22 1994-06-21 Hoffman-Laroche Inc. Reverse transcription with thermostable DNA polymerases - high temperature reverse transcription
US5310652A (en) 1986-08-22 1994-05-10 Hoffman-La Roche Inc. Reverse transcription with thermostable DNA polymerase-high temperature reverse transcription
ES2198514T3 (es) 1991-08-27 2004-02-01 F. Hoffmann-La Roche Ag Cebadores y sondas para la deteccion de la hepatitis c.
EP0532258A2 (en) * 1991-09-09 1993-03-17 Immuno Japan Inc. Oligonucleotides and determination system of HCV genotypes
JPH0775585A (ja) * 1993-06-14 1995-03-20 Immuno Japan:Kk Ｃ型肝炎ウイルス関連オリゴヌクレオチドならびにｃ型肝炎 ウイルス遺伝子型判定方法
ZA966663B (en) 1995-08-17 1998-02-06 Genentech Inc Traf Inhibitors.
US6153421A (en) * 1997-07-18 2000-11-28 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Cloned genomes of infectious hepatitis C viruses and uses thereof
WO2002064842A2 (en) * 2001-02-13 2002-08-22 Children`S Hospital Research Foundation Quantitative epstein barr virus pcr rapid assay
US20040137539A1 (en) * 2003-01-10 2004-07-15 Bradford Sherry A. Cancer comprehensive method for identifying cancer protein patterns and determination of cancer treatment strategies
BRPI0407587A (pt) 2003-02-18 2006-02-14 Pfizer inibidores do vìrus da hepatite c, composições e tratamentos que os utilizam
US20050282179A1 (en) 2003-12-05 2005-12-22 Applera Corporation Biomarkers for interferon-alpha response in hepatitis C virus infected patients

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003088382A (ja) * 2001-09-18 2003-03-25 Toshiba Corp インターフェロンを投与されるべき個体においてインターフェロン療法の有効性を予測する方法、その方法をコンピュータにより実行させるためのプログラム、インターフェロン感受性に関連する多型部位の遺伝子型を検出するための核酸プローブ、およびその核酸プローブを具備する塩基配列検出用チップ
WO2003085084A2 (en) * 2002-04-03 2003-10-16 Smithkline Beecham Corporation Hepatitis c virus sub-genomic replicons
WO2006085407A1 (ja) * 2005-02-09 2006-08-17 Nihon University Hcv量に関連する遺伝子のスクリーニング方法
WO2008136470A1 (ja) * 2007-04-27 2008-11-13 Advanced Life Science Institute, Inc. Ｈｃｖ遺伝子
JP2008005849A (ja) * 2007-08-10 2008-01-17 Toshiba Corp 標的核酸の遺伝子型、および変異の判定方法、不溶性支持体に核酸断片を固定化する方法、所望の核酸を精製し、かつ増幅するための方法、並びに遺伝子型アッセイキット

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JPN6014027670; ＣＨＯＩ Ｊ ｅｔ ａｌ．， Ｄａｔａｂａｓｅ ＧｅｎＢａｎｋ［ｏｎｌｉｎｅ］， Ａｃｃｅｓｓｉｏｎ Ｎｏ．ＮＣ＿００４１０２， ＜ｈｔｔｐ：／／ｗｗｗ．ｎｃｂｉ．ｎｌｍ．ｎｉｈ．ｇｏｖ／ｎｕｃｃｏ *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022513704A (ja) * 2018-12-03 2022-02-09 ダイアグノスティクス フォー ザ リアル ワールド， リミテッド Ｈｃｖ検出
JP7702867B2 (ja) 2018-12-03 2025-07-04 ダイアグノスティクス フォー ザ リアル ワールド， リミテッド Ｈｃｖ検出

Also Published As

Publication number Publication date
US20120129155A1 (en) 2012-05-24
EP2389452A2 (en) 2011-11-30
NZ594155A (en) 2013-02-22
US8679740B2 (en) 2014-03-25
ZA201105349B (en) 2013-10-30
CN102341506A (zh) 2012-02-01
WO2010090857A3 (en) 2010-11-25
WO2010090857A8 (en) 2012-06-28
MX2011007693A (es) 2011-09-27
RU2011134857A (ru) 2013-02-27
KR20120101278A (ko) 2012-09-13
CA2749969A1 (en) 2010-08-12
US20140199684A1 (en) 2014-07-17
IL214195A0 (en) 2011-08-31
AU2010210892A1 (en) 2011-08-11
WO2010090857A2 (en) 2010-08-12

Similar Documents

Publication Publication Date Title
US8679740B2 (en) Methods for amplifying hepatitis C virus nucleic acids
JP2012515534A5 (enExample)
US8945833B2 (en) Method for determining drug resistance mutations in any of the non-structural protein regions NS3 to NS5B of hepatitis C virus (HCV) for genotypes 1 to 6
EP3126530B1 (en) Method for specific detection of classical swine fever virus
CN1882690B (zh) 从新hcv株衍生的核酸和基因以及使用所述基因的复制子-复制细胞
US10202659B2 (en) Primers and methods for detecting human hepatitis C virus (HCV) variants in an isolated sample
JPH07184695A (ja) Ｃ型肝炎ウイルスの簡易検出法
US20210214810A1 (en) Reagents and Methods for Detecting HCV
Papin et al. Genome-wide real-time PCR for West Nile virus reduces the false-negative rate and facilitates new strain discovery
JP5607532B2 (ja) Ｈｃｖ薬剤抵抗性のほぼ全ゲノムのアッセイ
EP1721015B1 (en) Primer and probe design for efficient amplification and detection of hcv 3' non-translating region
JP4624515B2 (ja) Ｃ型肝炎ウイルス（ｈｃｖ）ｒｎａの効率的逆転写のためのオリゴヌクレオチドプライマーおよびそれの使用方法
US20160177407A1 (en) Method for determining drug resistance mutations in any of the non-structural protein regions ns3 to ns5b of hepatitis c virus (hcv) for genotypes 1 to 6
EP1616967B1 (en) Primers for isothermal amplification and genotyping of Hepatitis C virus
HK1163188A (en) Methods for amplifying hepatitis c virus nucleic acids
JP7702867B2 (ja) Ｈｃｖ検出
Zhang et al. Enhanced protocol for determining the 3′ terminus of hepatitis C virus

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130117

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130117

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140701

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150107